Review



soluble fms like tyrosine kinase 1  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    R&D Systems soluble fms like tyrosine kinase 1
    Soluble Fms Like Tyrosine Kinase 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1247 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/neutralizing+antibodies+against+sflt-1/Human+IL-6+DuoSet+ELISA/10__1002_slash_jlb__3ma0620___728rr-60-6-25
    Average 99 stars, based on 1247 article reviews
    soluble fms like tyrosine kinase 1 - by Bioz Stars, 2026-09
    99/100 stars

    Images

    Related Articles

    Enzyme-linked Immunosorbent Assay:

    Article Title: Intercellular transfer of LncRNA NEAT1 drives post-infarction inflammation by blocking the macrophage IRG1-itaconate metabolic axis
    Article Snippet: cluding monocyte chemoattractant protein-1 (MCP-1), keratinocyte chemoattractant (KC), TNF-α, interleukin (IL)-1β, and IL-6, were quantified in myocardial tissue homogenates using specific ELISA kits (R&D Systems, DCP00 for MCP-1, DTA00D for TNF-α, DLB50 for IL-1β, DY206 for IL-6, Shanghai, China; Merck, RAB0117 for KC) homogenized in ice-cold PBS (Beyotime, C0221A) supplemented with a protease inh

    Protease Inhibitor:

    Article Title: Intercellular transfer of LncRNA NEAT1 drives post-infarction inflammation by blocking the macrophage IRG1-itaconate metabolic axis
    Article Snippet: cluding monocyte chemoattractant protein-1 (MCP-1), keratinocyte chemoattractant (KC), TNF-α, interleukin (IL)-1β, and IL-6, were quantified in myocardial tissue homogenates using specific ELISA kits (R&D Systems, DCP00 for MCP-1, DTA00D for TNF-α, DLB50 for IL-1β, DY206 for IL-6, Shanghai, China; Merck, RAB0117 for KC) homogenized in ice-cold PBS (Beyotime, C0221A) supplemented with a protease inh

    Milk:

    Article Title: Intercellular transfer of LncRNA NEAT1 drives post-infarction inflammation by blocking the macrophage IRG1-itaconate metabolic axis
    Article Snippet: cluding monocyte chemoattractant protein-1 (MCP-1), keratinocyte chemoattractant (KC), TNF-α, interleukin (IL)-1β, and IL-6, were quantified in myocardial tissue homogenates using specific ELISA kits (R&D Systems, DCP00 for MCP-1, DTA00D for TNF-α, DLB50 for IL-1β, DY206 for IL-6, Shanghai, China; Merck, RAB0117 for KC) homogenized in ice-cold PBS (Beyotime, C0221A) supplemented with a protease inh

    Cell Culture:

    Article Title: Intercellular transfer of LncRNA NEAT1 drives post-infarction inflammation by blocking the macrophage IRG1-itaconate metabolic axis
    Article Snippet: cluding monocyte chemoattractant protein-1 (MCP-1), keratinocyte chemoattractant (KC), TNF-α, interleukin (IL)-1β, and IL-6, were quantified in myocardial tissue homogenates using specific ELISA kits (R&D Systems, DCP00 for MCP-1, DTA00D for TNF-α, DLB50 for IL-1β, DY206 for IL-6, Shanghai, China; Merck, RAB0117 for KC) homogenized in ice-cold PBS (Beyotime, C0221A) supplemented with a protease inh

    Spectrophotometry:

    Article Title: Intercellular transfer of LncRNA NEAT1 drives post-infarction inflammation by blocking the macrophage IRG1-itaconate metabolic axis
    Article Snippet: cluding monocyte chemoattractant protein-1 (MCP-1), keratinocyte chemoattractant (KC), TNF-α, interleukin (IL)-1β, and IL-6, were quantified in myocardial tissue homogenates using specific ELISA kits (R&D Systems, DCP00 for MCP-1, DTA00D for TNF-α, DLB50 for IL-1β, DY206 for IL-6, Shanghai, China; Merck, RAB0117 for KC) homogenized in ice-cold PBS (Beyotime, C0221A) supplemented with a protease inh

    Imaging:

    Article Title: Intercellular transfer of LncRNA NEAT1 drives post-infarction inflammation by blocking the macrophage IRG1-itaconate metabolic axis
    Article Snippet: cluding monocyte chemoattractant protein-1 (MCP-1), keratinocyte chemoattractant (KC), TNF-α, interleukin (IL)-1β, and IL-6, were quantified in myocardial tissue homogenates using specific ELISA kits (R&D Systems, DCP00 for MCP-1, DTA00D for TNF-α, DLB50 for IL-1β, DY206 for IL-6, Shanghai, China; Merck, RAB0117 for KC) homogenized in ice-cold PBS (Beyotime, C0221A) supplemented with a protease inh

    Software:

    Article Title: Intercellular transfer of LncRNA NEAT1 drives post-infarction inflammation by blocking the macrophage IRG1-itaconate metabolic axis
    Article Snippet: cluding monocyte chemoattractant protein-1 (MCP-1), keratinocyte chemoattractant (KC), TNF-α, interleukin (IL)-1β, and IL-6, were quantified in myocardial tissue homogenates using specific ELISA kits (R&D Systems, DCP00 for MCP-1, DTA00D for TNF-α, DLB50 for IL-1β, DY206 for IL-6, Shanghai, China; Merck, RAB0117 for KC) homogenized in ice-cold PBS (Beyotime, C0221A) supplemented with a protease inh

    Staining:

    Article Title: Intercellular transfer of LncRNA NEAT1 drives post-infarction inflammation by blocking the macrophage IRG1-itaconate metabolic axis
    Article Snippet: cluding monocyte chemoattractant protein-1 (MCP-1), keratinocyte chemoattractant (KC), TNF-α, interleukin (IL)-1β, and IL-6, were quantified in myocardial tissue homogenates using specific ELISA kits (R&D Systems, DCP00 for MCP-1, DTA00D for TNF-α, DLB50 for IL-1β, DY206 for IL-6, Shanghai, China; Merck, RAB0117 for KC) homogenized in ice-cold PBS (Beyotime, C0221A) supplemented with a protease inh

    Recombinant:

    Article Title: Intercellular transfer of LncRNA NEAT1 drives post-infarction inflammation by blocking the macrophage IRG1-itaconate metabolic axis
    Article Snippet: cluding monocyte chemoattractant protein-1 (MCP-1), keratinocyte chemoattractant (KC), TNF-α, interleukin (IL)-1β, and IL-6, were quantified in myocardial tissue homogenates using specific ELISA kits (R&D Systems, DCP00 for MCP-1, DTA00D for TNF-α, DLB50 for IL-1β, DY206 for IL-6, Shanghai, China; Merck, RAB0117 for KC) homogenized in ice-cold PBS (Beyotime, C0221A) supplemented with a protease inh

    Modification:

    Article Title: Intercellular transfer of LncRNA NEAT1 drives post-infarction inflammation by blocking the macrophage IRG1-itaconate metabolic axis
    Article Snippet: cluding monocyte chemoattractant protein-1 (MCP-1), keratinocyte chemoattractant (KC), TNF-α, interleukin (IL)-1β, and IL-6, were quantified in myocardial tissue homogenates using specific ELISA kits (R&D Systems, DCP00 for MCP-1, DTA00D for TNF-α, DLB50 for IL-1β, DY206 for IL-6, Shanghai, China; Merck, RAB0117 for KC) homogenized in ice-cold PBS (Beyotime, C0221A) supplemented with a protease inh

    RNA sequencing:

    Article Title: Intercellular transfer of LncRNA NEAT1 drives post-infarction inflammation by blocking the macrophage IRG1-itaconate metabolic axis
    Article Snippet: cluding monocyte chemoattractant protein-1 (MCP-1), keratinocyte chemoattractant (KC), TNF-α, interleukin (IL)-1β, and IL-6, were quantified in myocardial tissue homogenates using specific ELISA kits (R&D Systems, DCP00 for MCP-1, DTA00D for TNF-α, DLB50 for IL-1β, DY206 for IL-6, Shanghai, China; Merck, RAB0117 for KC) homogenized in ice-cold PBS (Beyotime, C0221A) supplemented with a protease inh

    Control:

    Article Title: Intercellular transfer of LncRNA NEAT1 drives post-infarction inflammation by blocking the macrophage IRG1-itaconate metabolic axis
    Article Snippet: cluding monocyte chemoattractant protein-1 (MCP-1), keratinocyte chemoattractant (KC), TNF-α, interleukin (IL)-1β, and IL-6, were quantified in myocardial tissue homogenates using specific ELISA kits (R&D Systems, DCP00 for MCP-1, DTA00D for TNF-α, DLB50 for IL-1β, DY206 for IL-6, Shanghai, China; Merck, RAB0117 for KC) homogenized in ice-cold PBS (Beyotime, C0221A) supplemented with a protease inh



    Similar Products

    90
    R&D Systems neutralizing antibodies against sflt-1
    Exogenous recombinant Wnt5a mediates SVFs vascular self-assembly. SVFs were treated with increasing concentrations of recombinant Wnt5a: (a and b) The effects of various concentrations of recombinant Wnt5a on neovascularization in Matrigel plugs. After stimulation with different concentrations of recombinant Wnt5a, the plugs were removed on day 14 after Matrigel injection for the visualization and quantification of angiogenesis. Representative photographs of plugs from groups of five animals are shown. Quantification of angiogenesis within the Matrigel plugs is shown for all conditions. (c and d) During stimulation with different concentrations of Wnt5a, the expression of the vascularization-stimulating factors MMP2, MMP9, VEGFR2, and <t>sFlt-1</t> in SVFs gradually increased. (e and f) At 4 weeks, the expression of Wnt5a and the vascular inhibitor sFlt-1 in the SVF-BAM group simultaneously increased. *p < 0.05; **p < 0.01; ***p < 0.005.
    Neutralizing Antibodies Against Sflt 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/neutralizing+antibodies+against+sflt-1/vegf+elisa+kit/pmc06886281-71-30-35
    Average 90 stars, based on 1 article reviews
    neutralizing antibodies against sflt-1 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    Image Search Results


    Exogenous recombinant Wnt5a mediates SVFs vascular self-assembly. SVFs were treated with increasing concentrations of recombinant Wnt5a: (a and b) The effects of various concentrations of recombinant Wnt5a on neovascularization in Matrigel plugs. After stimulation with different concentrations of recombinant Wnt5a, the plugs were removed on day 14 after Matrigel injection for the visualization and quantification of angiogenesis. Representative photographs of plugs from groups of five animals are shown. Quantification of angiogenesis within the Matrigel plugs is shown for all conditions. (c and d) During stimulation with different concentrations of Wnt5a, the expression of the vascularization-stimulating factors MMP2, MMP9, VEGFR2, and sFlt-1 in SVFs gradually increased. (e and f) At 4 weeks, the expression of Wnt5a and the vascular inhibitor sFlt-1 in the SVF-BAM group simultaneously increased. *p < 0.05; **p < 0.01; ***p < 0.005.

    Journal: Journal of Tissue Engineering

    Article Title: Construction of a vascularized bladder with autologous adipose-derived stromal vascular fraction cells combined with bladder acellular matrix via tissue engineering

    doi: 10.1177/2041731419891256

    Figure Lengend Snippet: Exogenous recombinant Wnt5a mediates SVFs vascular self-assembly. SVFs were treated with increasing concentrations of recombinant Wnt5a: (a and b) The effects of various concentrations of recombinant Wnt5a on neovascularization in Matrigel plugs. After stimulation with different concentrations of recombinant Wnt5a, the plugs were removed on day 14 after Matrigel injection for the visualization and quantification of angiogenesis. Representative photographs of plugs from groups of five animals are shown. Quantification of angiogenesis within the Matrigel plugs is shown for all conditions. (c and d) During stimulation with different concentrations of Wnt5a, the expression of the vascularization-stimulating factors MMP2, MMP9, VEGFR2, and sFlt-1 in SVFs gradually increased. (e and f) At 4 weeks, the expression of Wnt5a and the vascular inhibitor sFlt-1 in the SVF-BAM group simultaneously increased. *p < 0.05; **p < 0.01; ***p < 0.005.

    Article Snippet: Briefly, 2.5 × 10 5 SVFs were treated with five different concentrations of recombinant human Wnt5a (0, 10, 50, 100, and 200 ng/mL; R&D Systems, Minneapolis, MN, USA) or neutralizing antibodies against sFlt-1 (10 µg/mL; R&D Systems) premixed with Matrigel (1 mg/mL) and EGM-2, and injected subcutaneously into nude mice in both inguinal regions.

    Techniques: Recombinant, Injection, Expressing

    sFlt-1 suppresses the angiogenesis of SVFs: (a) Tube formation assays in SVFs treated with sFlt-1 neutralizing antibody, magnification ×40 and (b) Matrigel plug angiogenesis assay in SVFs treated with sFlt-1 neutralizing antibody. **p < 0.01.

    Journal: Journal of Tissue Engineering

    Article Title: Construction of a vascularized bladder with autologous adipose-derived stromal vascular fraction cells combined with bladder acellular matrix via tissue engineering

    doi: 10.1177/2041731419891256

    Figure Lengend Snippet: sFlt-1 suppresses the angiogenesis of SVFs: (a) Tube formation assays in SVFs treated with sFlt-1 neutralizing antibody, magnification ×40 and (b) Matrigel plug angiogenesis assay in SVFs treated with sFlt-1 neutralizing antibody. **p < 0.01.

    Article Snippet: Briefly, 2.5 × 10 5 SVFs were treated with five different concentrations of recombinant human Wnt5a (0, 10, 50, 100, and 200 ng/mL; R&D Systems, Minneapolis, MN, USA) or neutralizing antibodies against sFlt-1 (10 µg/mL; R&D Systems) premixed with Matrigel (1 mg/mL) and EGM-2, and injected subcutaneously into nude mice in both inguinal regions.

    Techniques: Angiogenesis Assay